Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
Speaker 2: The Stock Movers report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg data recording,
Speaker 2: we've factoring on the screen all those stocks are off
Speaker 2: their highs but still holding on some gains.
Speaker 1: To take a look at some of the stocks on
Speaker 1: the move today, and we can do that with that
Speaker 1: line for now Equities reporter for Bloomberg News joining us
Speaker 1: live here in studio alone. What are you looking at?
Speaker 3: We have to start off with spacexets ticker SPCX. It's
Speaker 3: currently falling about eight point two percent, most since July first,
Speaker 3: and that' stuffed a company's first earnings release left investors
Speaker 3: wanting a little bit more. At issue was higher than
Speaker 3: expected spending in the company's AI unit, which really weighed
Speaker 3: on cash flow. Capex stored to nearly twenty nine billion
Speaker 3: dollars in the first half of this year, which is
Speaker 3: more than four times at spending just a year earlier.
Speaker 3: Oppenheimer highlighting that the capex levels are a major concern
Speaker 3: for investors, especially considering that SpaceX will need more than
Speaker 3: four hundred billion dollars in funding to hit break even.
Speaker 3: Piper Sandler, also adding that the lock up expiration is
Speaker 3: also contributing to stock weakness today, so we'll definitely be
Speaker 3: keeping an eye on it tomorrow as those one hundred
Speaker 3: and one billion dollars worth of shares become available for
Speaker 3: trading tomorrow.
Speaker 1: Yeah, definitely another headwind for this stock that remain as
Speaker 1: well below the one thirty five IPO price. All right,
Speaker 1: let's stick with the earning season theme. Yes, Eli Lilly.
Speaker 3: That's ticker LLY. It was up nearly nine percent earlier
Speaker 3: but now only up about two point two percent. That's
Speaker 3: after the firm's better than expected second quarter results led
Speaker 3: to a boost in twenty twenty six sales guidance BMO,
Speaker 3: highlighting that Lily again raised the bar with another beat
Speaker 3: and raised quarter, also noting that the relatively inline quarter
Speaker 3: for Lily's weight loss pill FOUNDEO is also likely sufficient
Speaker 3: given declining expectations for the drug Worf, noting that these
Speaker 3: results are definitely going to suage some fears from investors
Speaker 3: at the obest drug boom is starting to slow down,
Speaker 3: especially after their rival Novo Nordis reported a little bit
Speaker 3: softer will go be pill sales?
Speaker 1: Last one here I don't know. DaVita Davida.
Speaker 3: Yes, DaVita is definitely something that we will also be
Speaker 3: talking about. That's tickert DVA. It fell nearly nineteen percent
Speaker 3: today and that's partially because their US dialysis revenue missed estimates.
Speaker 3: Part of that is definitely because of their treatment center growth.
Speaker 3: Barclay is actually pointing out that while they have made
Speaker 3: a lot of progress on treatment growth, the US dialysis
Speaker 3: ebit continues to fall short, and that's definitely ahead when
Speaker 3: that people will be watching. Also worth noting that the
Speaker 3: firm reaffirmed it is for your guidance, with the midpoint
Speaker 3: of that guidance now falling below Wall Street's expectations as well.
Speaker 1: All right, Avalon, thank you so much for that wrap
Speaker 1: up of Stocks on the Move.
Speaker 2: The Stock Movers Report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business app.